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Abstract
Purpose—The effects of omeprazole on indinavir when administered alone or in combination with
ritonavir were evaluated.
Methods—Fourteen men and women age 18–55 years not infected with human immunodeficiency
virus who met study qualifications were randomized to receive placebo, 20 mg of omeprazole, or 40
mg of omeprazole daily. After seven days, the single-dose pharmacokinetic profile of an 800-mg
dose of indinavir alone or in combination with 200 mg of ritonavir was evaluated. Study participants
received each of four study regimens in one of four randomly assigned orders. Blood samples were
collected, and plasma indinavir and ritonavir concentrations were analyzed using high-performance
liquid chromatography.
Results—The coadministration of 20 or 40 mg of omeprazole with indinavir significantly reduced
the mean indinavir area under the concentration-versus-time curve (AUC) from 30.0 mg · hr/L (95%
confidence interval [CI], 21.9–41.1 mg · hr/L) to 19.7 mg · hr/L (95% CI, 14.6–26.8 mg · hr/L) or
16.0 mg · hr/L (95% CI, 11.8–21.7 mg · hr/L), respectively (p < 0.002). The addition of 200 mg of
ritonavir to 800 mg of indinavir in combination with 40 mg of omeprazole significantly increased
the mean indinavir AUC from 30.0 mg · hr/L (95% CI, 21.9–41.1 mg · hr/L) to 46.6 mg · hr/L (95%
CI, 34.0–63.8 mg · hr/L), but it did not significantly affect mean omeprazole concentrations (p ≤
0.02).
Conclusion—The AUC of indinavir was substantially decreased in healthy volunteers who
received omeprazole 20 or 40 mg daily for seven days before the administration of a single 800-mg
dose of indinavir. Concomitant administration of ritonavir 200 mg with indinavir in participants
receiving omeprazole led to a significant increase in the AUC of indinavir.
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Protease inhibitors (PIs) exhibit a high degree of pharmacokinetic variability in patients
infected with the human immunodeficiency virus (HIV).1,2 Large interindividual differences
in drug absorption and elimination in HIV-infected patients have been primarily attributed to
constitutive or altered drug metabolizing enzymes, P-glycoprotein transporter activities, and
poor drug solubility.3 With the PIs indinavir and atazanavir, changes in gastric pH can alter
drug absorption.4,5 Specifically, when these PIs are administered with medications that
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increase gastric pH, such as histamine (H2)-receptor antagonists and proton-pump inhibitors
(PPIs), bioavailability can decrease by up to 76%.4,6
A survey of 200 HIV-infected patients was performed to assess their use of drugs that affect
gastric acidity.7 Fifty-six percent of HIV-infected patients who had recently begun highly
active antiretroviral therapy (HAART) had taken nonprescription acid-reducing agents, and
39% had used both nonprescription and prescription products for acid reduction. Forty-six
percent of patients on a PI-containing regimen had used PPIs or H2-receptor antagonists once
they started HAART, and 35% had used them within the previous 12 months. This widespread
use of acid-reducing agents among HIV-infected patients has implications for drug interactions
with antiretrovirals and other medications that require an acidic environment for adequate
dissolution and absorption.
Ritonavir is a cytochrome P-450 (CYP) isoenzyme 3A and P-glycoprotein inhibitor which,
when used in low doses, can increase the exposure of concomitantly administered PIs. The
concomitant administration of ritonavir with atazanavir to enhance the absorption of atazanavir
when used concurrently with acid-reducing agents has been investigated.7 While these studies
show that concomitant administration of ritonavir does not adequately increase atazanavir
exposure in the presence of PPIs, it does maintain adequate atazanavir exposure in the presence
of H2-receptor antagonists.4,8
The dissolution and absorption of indinavir are also dependent on an acidic environment.5 Due
to the paucity of data on indinavir combined with omeprazole, we conducted a prospective,
randomized, placebo-controlled, single-dose crossover study to evaluate the influence of two
different doses of omeprazole on indinavir pharmacokinetics.
Methods
Participants
Sixteen HIV-uninfected men and women ages 18 to 55 years were recruited for this study,
which was approved by the institutional review board of the University of North Carolina
(UNC) at Chapel Hill, School of Medicine. Informed consent was obtained from all volunteers
before study screening. Women of childbearing age were required to have a negative serum or
urine β-human chorionic gonadotropin test at screening. All participants were tested for HIV
antibodies using the standard blood test procedure (enzyme-linked immunosorbent assay
[ELISA] plus West blot). Participants were excluded if they had any of the following disorders:
active gastrointestinal disease (including, but not limited to, peptic ulcer disease and
gastroesophageal reflux disease), liver disease based on laboratory test results (aspartate
transaminase, alanine transaminase, or a total bilirubin level of >3.0 times the upper limit of
normal), prior allergy or intolerance to any study medication, renal disease (serum creatinine
of ≥1.5 mg/dL), a history of nephrolithiasis, or active drug or alcohol abuse or dependence that
would interfere with adherence to study requirements. Concomitant use of other medications
known to influence CYP, drug transporter activity, or gastric pH was not permitted.
Study design
Participants were assigned by means of a permuted block randomization algorithm into one of
four groups. Each group completed four visits. The patients were randomized to receive seven
days of placebo daily (visit A), 20 mg of omeprazole daily (visit B), or 40 mg of omeprazole
daily (visits C and D). After seven days, the single-dose pharmacokinetics of an 800-mg dose
of indinavir (Crixivan, Merck & Co., Inc., Whitehouse Station, NJ) (visits A, B, and C) or
indinavir 800 mg administered in combination with 200 mg of ritonavir (Norvir, Abbott
Laboratories, Abbott Park, IL) (visit D) was evaluated. Each visit was separated by at least a
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seven-day washout period to allow for the elimination of omeprazole and to avoid treatment-
by-period interactions. Participants were given placebo and a single dose of indinavir for period
A, omeprazole 20 mg and a single dose of indinavir for period B, omeprazole 40 mg and a
single dose of indinavir for period C, and omeprazole 40 mg and a single dose of indinavir plus
ritonavir for period D. Participants received each of the four study regimens in one of four
randomly assigned orders: Group 1—A, D, C, B; Group 2—B, C, D, A; Group 3—C, B, A,
D; and Group 4—D, A, B, C. Before the morning of the seventh day of each visit, patients
were admitted to the General Clinical Research Center at UNC Hospitals. A complete physical
examination was performed, and laboratory test results (blood chemistry profiles, liver function
tests, and complete blood counts with differential) were obtained. The occurrence of study-
related adverse effects was assessed at each visit by study personnel and graded according to
the adult AIDS Clinical Trials Group (ACTG) criteria.9
At 8:00 on the morning of the 7th, 21st, 35th, and 49th days, patients received either 800 mg
of indinavir orally or 800 mg of indinavir with 200 mg of ritonavir orally in addition to
omeprazole or placebo. Participants receiving indinavir without ritonavir were given a low-fat
breakfast (446 kcal, 3.2 g fat, 12.2 g protein, and 95.2 g carbohydrates) one hour after indinavir
was administered. Participants receiving indinavir with ritonavir were given a standardized,
normal meal (905 kcal, 31.9 g fat, 33 g protein, and 116.7 g carbohydrates) at the time of
medication administration. The drugs were administered with meals based on the
manufacturer’s dosing recommendations.6 Since participants received single doses of
indinavir, we did not deem them at risk for nephrolithiasis; thus, participants were not required
to drink ≥1.5–2 L of liquid per day when taking indinavir, as recommended by the
manufacturer.
Blood sampling was performed over 24 hours after the observed administration of the indinavir
or indinavir and ritonavir doses at the following intervals: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 18,
and 24 hours. A total of 10 mL of blood was collected in tubes containing
tripotassiumethylenediaminetetraacetic acid as the anticoagulanta and centrifuged for 15
minutes at 3000 rpm at 2 °C. Four 1-mL cryogenic vials were filled with plasma supernatant
and stored temporarily at −20 °C until all samples from each visit had been collected. Samples
were then transferred to a −70 °C freezer until analysis.
All study medications were prepared and dispensed by the hospital’s investigational drugs
pharmacy. Doses were prepared in nontransparent, darkly colored capsules containing either
20 or 40 mg of omeprazole or placebo tablets containing lactose, steric acid, and magnesium
stearate. Medication adherence was assessed at each study visit by pill count or direct
observation by research staff.
Sample analyses
Plasma indinavir and ritonavir concentrations were analyzed according to a high-performance
liquid chromatography (HPLC) method with ultraviolet detection as described by Rezk and
colleagues.10 Briefly, a standard stock solution of indinavir and ritonavir was prepared at a 1-
mg/mL concentration in composite with other PIs and nonnucleosides. A 550-μL plasma
sample was mixed with 550 μL of 125-mM ammonium acetate containing an internal standard
(midazolam) and subjected to solid-phase extraction using BOND ELUT-C18 columns (1.0
mL, 100 mg)b The eluted samples were evaporated and reconstituted in 100 μL of mobile phase
before injection into the HPLC system.c The mobile phase consisted of (A) 50 mM of phosphate
monobasic (pH 4.5) 85% mixed with methanol 15% and (B) 250 mL of buffer as mobile phase
aVacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ.
bBOND ELUT-C18, Varian, Inc., Harbor City, CA.
cSeries 1100 HPLC System, Agilent Technologies, Wilmington, DE.
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A, mixed with 600 mL of acetonitrile, 150 mL of methanol, and 0.75 mL of trifluoroacetic
acid. Chromatographic separation was accomplished with an analytical column (3.5 μm, 150
× 4.6 mm)d and a guard column (3.5 μm, 12.5 × 4.6 mm).e Separation was facilitated via a
linear-gradient elution of mobile phase as 36–86% of mobile phase (B) and a mobile-phase
flow rate gradient of 0.9–1.2 mL over 30 minutes. Calibration standard curves ranged from 10
to 10,000 ng/mL. Intraday and interday variations for indinavir and ritonavir were <2.3% and
<1.2%, respectively.
Plasma extraction and detection of omeprazole were adapted from a previously published
method.11 Briefly, 200 ng of internal standard, H153/52,f 400 μL of 0.5 M potassium phosphate
buffer solution (pH 8.0), 50 mg of sodium chloride, and 1.5 mL of dichloromethane were added
to 1 mL of plasma. Samples were vortexed and centrifuged, and the lower dichloromethane
layer was evaporated to dryness under nitrogen at room temperature. Samples were
reconstituted in 150 μL of mobile phase, and 100 μL of that solution was injected onto a
CAPCELL PAK UG 120 (2 × 250 mm) 5-μm particle-size column.g The mobile phase
consisted of acetonitrile with 0.05 M sodium phosphate buffer (pH 8.5) (27:73, by volume)
delivered at a flow rate of 0.3 mL/min. The detection wavelength was fixed at 302 nm.
Integration was performed using HP ChemStation software.h Standard curves were linear and
reproducible over the concentration range of 100–10,000 ng/mL. Intraday and interday
variability was ≤15%.
Data analysis
The pharmacokinetic parameters for indinavir and ritonavir were evaluated from plasma drug
concentration data using a non-compartmental analysis.i Indinavir’s and omeprazole’s
maximum plasma concentration (Cmax) and time to Cmax (tmax) were obtained from direct
observation of the data. The area under the concentration-versus-time curve from zero to 24
hours (AUC0-24) was calculated using the linear trapezoidal rule.
A linear mixed-effect model with a compound symmetry covariance structure was used to
compare the AUCs of indinavir and omeprazole, and a regression analysis was performed
comparing omeprazole AUCs and indinavir exposures.j The study sample size was calculated
to have 90% power to detect a 50% decrease in indinavir AUC. All data were expressed as the
geometric mean (95% confidence interval [CI]) unless otherwise stated.
Results
Sixteen volunteers were screened for enrollment and 14 participants completed all four visits;
two participants were excluded due to their difficulty in obtaining an i.v. access and their
inability to swallow capsules. Of those remaining 14 participants, 7 were men, 11 were
Caucasian, 2 were African American, and 1 was Hispanic. The mean age for these participants
was 32 years (range, 23–59 years). No severe adverse events occurred during the study.
Adverse events included ACTG criteria grade 1 gastrointestinal upset in one participant and a
grade 1 elevation in the bilirubin level of another participant during treatment with 800 mg of
indinavir, 200 mg of ritonavir, and 40 mg of omeprazole. No participants discontinued the
study due to adverse events. The pharmacokinetics for each of the regimens is summarized in
Figure 1 and Table 1.
dZorbax C-18 analytical column, Agilent Technologies.
eZorbax C-18 guard column, Agilent Technologies.
fOmeprazole standard (H153/52), Astra, Sweden.
gCAPCELL PAK UG column, Shiseido Co. Ltd., Tokyo, Japan.
hHP ChemStation software, Hewlett Packard, Germany.
iWinNonlin, V4.01, Pharsight Corporation, Mountainview, CA.
jSAS PROC MIXED, version 8, SAS Institute, Inc., Cary, NC.
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Pretreatment and coadministration of a 20- or 40-mg dose of omeprazole decreased indinavir
exposure after a single-dose administration of 800 mg of indinavir. When compared with
placebo, omeprazole 20 mg reduced the geometric mean indinavir AUC from 30.0 mg · hr/L
(95% CI, 21.9–41.1 mg · hr/L) to 19.7 mg · hr/L (95% CI, 14.6–26.8 mg · hr/L), but the
difference did not reach statistical significance. No statistically significant change was noted
in indinavir’s Cmax or tmax after the addition of omeprazole. The minimum plasma
concentrations (Cmin) of indinavir were not evaluated.
When compared with placebo, omeprazole 40 mg significantly decreased the geometric mean
AUC of indinavir from 30.0 mg · hr/L (95% CI, 21.9–41.1 mg · hr/L) to 16.0 mg · hr/L (95%
CI, 11.8–21.7 mg · hr/L). Similar to the 20-mg dose of omeprazole, no statistically significant
change was noted in indinavir’s Cmax or tmax. There were no statistically significant differences
in AUC, Cmax, and tmax between the 20- and 40-mg omeprazole dosing groups (p ≥ 0.32).
The addition of 200 mg of ritonavir to the 800-mg dose of indinavir after omeprazole 40-mg
pretreatment significantly increased the mean indinavir AUC from 16.0 mg · hr/L (95% CI,
11.8–21.7 mg · hr/L) to 46.6 mg · hr/L (95% CI, 34.0–63.8 mg · hr/L). This indinavir AUC
was also significantly higher than the indinavir AUC when administered with and after placebo.
Although the Cmax of indinavir was not significantly changed with the addition of ritonavir,
the tmax was significantly prolonged.
The addition of 200 mg of ritonavir to the 800-mg dose of indinavir after the omeprazole 40-
mg pretreatment did not significantly change the geometric mean ± S.E. omeprazole AUC (5.8
± 0.95 mg · hr/L without ritonavir to 6.1 ± 0.96 mg · hr/L with ritonavir). The mean ± S.E.
omeprazole AUC of 40 mg of omeprazole (with or without ritonavir) was significantly higher
than the mean ± S.E. omeprazole AUC of 20 mg of omeprazole (6.1 ± 0.96 or 5.8 ± 0.94 mg
· hr/L versus 1.9 ± 0.95 mg · hr/L, respectively; both p < 0.0001).
The Cmax ± S.E. of omeprazole was higher with 40 mg of omeprazole plus indinavir versus
the 40 mg of omeprazole plus indinavir with the addition of ritonavir (1230 ± 137 ng/mL versus
812 ± 141 ng/mL, p = 0.009). The mean ± S.E. half-life of omeprazole was prolonged with the
addition of ritonavir (1.6 ±0.4 hours versus 3.3 ± 0.4 hours, p = 0.0006). There was no
significant association between indinavir’s AUC and omeprazole’s AUC.
Discussion
Drug–drug interactions are a challenging aspect of managing patients infected with HIV. The
results of this study indicate that, for indinavir’s AUC, a significant drug–drug interaction with
PPIs may be overcome by the use of concomitant ritonavir therapy.
Indinavir is poorly soluble in water at physiological pH, with solubility decreasing as pH
increases.5 Additionally, indinavir absorption has been shown to be pH-dependent in rats and
dogs5 and meal-dependent in healthy volunteers and HIV-infected patients.6 Coadministration
of the H2-receptor antagonist cimetidine (600 mg twice daily) and indinavir (a single 400-mg
dose) minimally affected indinavir’s AUC.6 As cimetidine is also a CYP3A inhibitor, the
influence of the pH changes may have been confounded by the enzyme inhibitory effect.12
In a retrospective analysis of nine HIV-infected patients receiving a combination of indinavir
(800 mg three times daily) and omeprazole (20–40 mg daily), four patients had a plasma
indinavir AUC below the 95% CI of the average expected population indinavir AUC in patients
receiving indinavir alone.13
We chose to perform this pharmacokinetic analysis after a single dose of indinavir rather than
under steady-state conditions to decrease attrition, study duration, and medication-related
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adverse effects in otherwise healthy participants. Although these single-dose healthy-volunteer
data may not exactly replicate what would occur in an HIV-infected population, the data are
nonetheless compelling and should be considered. Since this study was performed, indinavir
use without ritonavir is no longer recommended in an antiretroviral regimen.14 Although
indinavir is not frequently used in the developed nations, its availability from generic
manufacturers in developing countries still makes indinavir data relevant to HIV treatment
worldwide.
To minimize the effect of interpatient variability, a crossover design was used. In the placebo
group (indinavir 800 mg alone), indinavir pharmacokinetics varied significantly but was
consistent with previously reported pharmacokinetic data.1 Indinavir’s AUC values in our
study ranged from 13.7 to 68.7 mg · hr/L and Cmax values ranged from 7,000 to 25,900 ng/mL.
However, these values were similar to or slightly higher than the indinavir AUC values reported
under steady-state conditions.6
As expected, seven days of omeprazole (40 mg) therapy before indinavir coadministration
decreased indinavir exposure. This change can be explained by decreased indinavir solubility
and absorption due to an increase in gastric pH. With concurrent administration of 20 mg of
omeprazole, the mean indinavir Cmax decreased by 29% and the mean tmax increased by 20%.
With 40 mg of omeprazole, the mean indinavir Cmax decreased by 41% and the mean indinavir
tmax increased by approximately 10%. With 20 and 40 mg of omeprazole therapy, the mean
indinavir AUC0-24 declined by 34% and 47%, respectively. Although there was a trend toward
a greater reduction in indinavir’s Cmax and AUC with 40 mg as compared with 20 mg of
omeprazole, these differences were not statistically significant. However, there was a
statistically significant reduction in the indinavir AUC between 40 mg omeprazole and placebo.
Our study was only powered to detect a 50% difference in the AUC between omeprazole 40
mg and placebo.
Coadministration of ritonavir has been shown to eliminate the need for food restrictions
(administration without food or with a low-fat meal) in patients receiving indinavir.15,16
However, this is the first study to demonstrate that coadministration of ritonavir with indinavir
may offset the pH-dependent decrease in indinavir exposure observed when coadministered
in single doses with omeprazole. An increase in indinavir’s AUC0-24 after coadministration of
ritonavir is well-known.17 Ritonavir 100 mg coadministered twice daily with 800 mg of
indinavir twice daily increases the indinavir Cmax by 1.6-fold and AUC0-24 by 2.7-fold
compared with 800 mg of indinavir given alone three times daily. Increasing the ritonavir dose
to 200 mg twice daily resulted in a 1.8-fold increase in the indinavir Cmax and a 3.6-fold increase
in the AUC0-24.6,17 In this study, 200 mg of ritonavir dosed with indinavir plus 40 mg of
omeprazole increased the AUC0-24 of indinavir alone by 2.9-fold compared with indinavir plus
40 mg of omeprazole. This exposure is comparable to historical data of a single dose of
indinavir 800 mg administered with 200 mg of ritonavir alone.13 In our study, the
administration of indinavir had no effect on the AUC and Cmax of omeprazole. The AUC and
Cmax of omeprazole observed in our study were similar to concentrations observed after
repeated administration of 40 mg of omeprazole alone.18
In a survey of nonprescription drug use among HIV-infected patients, 56% of patients reported
using acid-reducing agents,7 many of which are available without a prescription (e.g.,
cimetidine, famotidine, nizatidine, ranitidine, omeprazole). Due to the widespread use and
availability of these agents, many patients may be subject to interactions between antiretroviral
drugs and acid-suppressive therapy.
Fosamprenavir and atazanavir have also demonstrated pH-dependent solubility.4,19,20 In a
randomized, open-label, multiple-dose drug interaction study, a 76% decrease in the atazanavir
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AUC0-24 and a 78% decrease in the atazanavir Cmin were observed when atazanavir 300 mg
and ritonavir 100 mg were coadministered with omeprazole 40 mg. Increasing the dose of
atazanavir to 400 mg coadministered with 40 mg of omeprazole did not compensate for the
decrease in atazanavir exposure.8 Agarwala and colleagues21 evaluated patients receiving
atazanavir 300 mg plus ritonavir 100 mg daily coadministered with 40 mg of omeprazole and
observed a 61–76% decrease in the AUC of atazanavir. Another open-label crossover study
showed that administration of a single 400-mg dose of atazanavir with pretreatment and
coadministration of 60 mg of lansoprazole decreased the AUC of atazanavir by 94%.4
In one study, concomitant administration of ranitidine with a single dose of fosamprenavir
decreased amprenavir’s AUC and Cmax by 30% and 51%, respectively.19 In another study,
coadministration of esomeprazole with fosamprenavir with or without ritonavir had no
significant effects on the steady-state amprenavir AUC0-12, Cmax, or Cmin22; this lack of effect
may be partially attributable to the administration of fosamprenavir concurrently with
esomeprazole at the end of the esomeprazole dosing interval when the effect of gastric pH on
fosamprenavir dissolution would have been at a minimum.
Lopinavir, darunavir, and saquinavir pharmacokinetics have also been investigated when
combined with nonantacid gastric acid-reducing agents. Concomitant administration of
ranitidine, or omeprazole and lopinavir plus ritonavir, or darunavir plus ritonavir has not been
shown to significantly alter PI exposure.23-25 Coadministration of saquinavir plus ritonavir
with omeprazole has been shown to increase the saquinavir AUC by 82%.26
The data from this study are valuable in demonstrating the impact of combining PPIs with PIs,
which have pH-dependent absorption. As previous investigations with indinavir and H2-
receptor antagonists did not demonstrate an interaction, these data illustrate the need for drug-
interaction studies with both H2-receptor antagonists and PPIs. This concept is important for
the development of future PIs with pH-dependent absorption.
Caution should be taken when coadministering indinavir with a PPI. Strong consideration
should be given to coadministration with ritonavir, particularly in patients who are suspected
of having viral mutations that may cause reduced PI susceptibility.
Conclusion
The AUC of indinavir was substantially decreased in healthy volunteers who received
omeprazole 20 or 40 mg daily for seven days before administration of a single 800-mg dose
of indinavir. Concomitant administration of ritonavir 200 mg with indinavir in participants
receiving omeprazole led to a significant increase in the AUC of indinavir.
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Mean plasma indinavir concentration versus time profiles in study participants receiving
indinavir plus placebo, indinavir plus omeprazole 20 mg, indinavir plus omeprazole 40 mg,
and indinavir plus ritonavir and omeprazole 40 mg. Vertical bars indicate standard error of the
mean.
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Table 1
Pharmacokinetics of Indinavir for Each Study Regimena
Treatment
Geometric Mean AUC0-24 (95% CI) (mg
· hr/L) Geometric Mean Cmax (95% CI) (ng/mL) Geometric Mean tmax (95% CI) (hr)
Indinavir 800 mg plus
placebo
30.0 (21.9–41.1) 12,600 (9,300–17,200) 1.1 (0.3–1.9)
Indinavir 800 mg plus
omeprazole 20 mg
19.7 (14.6–26.8) 8,910 (6,530–12,200) 1.3 (0.5–2.1)
Indinavir 800 mg plus
omeprazole 40 mg
16.0 (11.8–21.7) 7,430 (5,510–10,000) 1.2 (0.4–2.0)
Indinavir 800 mg plus
omeprazole 40 mg plus
ritonavir 200 mg
46.6 (34.0–63.8) 6,590 (4,840–8,970) 4.1 (3.3–4.9)
a
CI = confidence interval.
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